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Abstract 
Thyroid dysfunctions such as hypothyroidism, thyrotoxicosis and thyroid nodules 
may develop during pregnancy leading to abortion, placental abruptions, 
preeclampsia, preterm delivery and reduced intellectual function in the offspring. 
Epidemiological data have shown the significant role of maternal thyroid hormone 
in fetal neurologic development and maternal health. It has been suggested that the 
deleterious effects of thyroid dysfunction can also extend beyond pregnancy and 
delivery to affect neuro-intellectual development in the early life of the child. 
Pregnancy poses an important challenge to the maternal thyroid gland as hormone 
requirements are increased during gestation as a result of an increase in thyroid- 
binding globulin, the stimulatory effect of HCG on TSH receptors, and increased 
peripheral thyroid hormone requirements. Maternal thyroid dysfunction is associated 
with increased risk for early abortion, preterm delivery,  neonatal morbidity and 
other obstetrical complications. Early diagnosis for thyroid dysfunction of pregnant 
women and treatment of thyroid dysfunction during pregnancy is important and cost 
effective to avoid both fetal and maternal complications secondary to thyroid 
dysfunction. Therefore the aim of this review was to assess the thyroid function 
changes occurring during pregnancy, the different disorders with their maternal and 
fetal implications, the laboratory diagnosis and the best ways of management of 
these conditions. 
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Introduction 
 
regnancy is a natural physiological 
changes that is accompanied with 
hormonic and metabolic alterations 
caused by a variety of conditions that results 
in many pathophysiologic processes, some of 
which have potentially serious outcomes if left 
untreated. Thyroid diseases during pregnancy 
are related to maternal and fetal 
complications. Therefore in this article, we try 
to review the thyroid function aberrations 
occurring during pregnancy, the different 
disorders with their maternal and fetal 
implications, the laboratory diagnosis and the 
best ways of management of these conditions. 
 
Physiological changes of thyroid function 
in mother and fetus during pregnancy 
Thyroid hormones (TH) are very important 
for growth and development of brain for the 
fetus and neonate, in addition for many other 
aspects of pregnancy, fetal growth and 
development (1). The thyroid gland 
dysfunctions like hypothyroidism and 
thyrotoxicosis can affect the mother health as 
well as the child before and after delivery that 
can result in fetal disease; in humans, this 
includes a high incidence of mental 
retardation (2). The fetal thyroid gland begins 
concentrating iodine and synthesizing THs 
after months of gestation. Although the 
requirement for TH before this time is 
exclusively supplied by the mother which is 
most important to fetal brain development, 
significant fetal brain development continues 
considerably beyond the first trimester (1, 2). 
Evident maternal thyroid failure during the first 
half of pregnancy has been associated with 
several pregnancy complications including 
preeclampsia, premature labor, fetal death 
and low birth weight and intellectual 
impairment in the offspring (3).  
THs have most profound effects on the 
terminal stages of fetal brain differentiation 
and development, including synaptogenesis, 
dendrites growth and axons myelination and 
neuronal migration. TH receptors are broadly 
dispersed in the fetal brain, and existing prior 
to the time the fetus is able to synthesize TH. 
P 
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Evidence  has confirmed that it is challenging 
to identify the molecular targets for TH action 
in the developing brain, but some 
improvement has been made (4, 5).  
 
Mechanisms of physiological changes of 
thyroid function in pregnancy 
Thyroid stimulation starts as early as the 
first trimester by β-HCG hormone, which 
shares some structural homology with thyroid-
stimulating hormone (TSH). There is also an 
estrogen-mediated increase in circulating 
levels of thyroid-binding globulin (TBG) during 
pregnancy by 2-3 times in serum TBG 
concentrations. TBG which is one of the 
numerous protein that transport TH in the 
blood with high affinity for thyroxine (T4) 
increases in serum a few weeks after 
conception and ranges a plateau during mid-
gestational period. The mechanism for this 
increase in TBG involves both increased hepatic 
synthesis of TBG and estrogen mediated 
perpetuation in sialylation of TBG that 
increases the half-life from 15 min to 3 days to 
fully sialylated TBG (6). 
Elevated levels of TBG lead to lowered free 
T4 concentrations, which results in increased 
TSH secretion by the pituitary and, 
subsequently, enhanced production and TH 
secretion. The net effect of elevated TBG 
synthesis is to force a new equilibrium 
between free and bound THs and therefore a 
substantial increase in total T4 and 
triiodothyronine (T3) levels. The augmented 
demand for THs is reached by about 20 wk of 
gestation and persists until term (6, 7). 
Reflecting changes in iodine metabolism, 
which is an essential requirement for TH 
synthesis, increased demand for iodine results 
from a significant pregnancy-associated 
increase in iodide clearance by the kidney and 
draw off maternal iodide by the fetus. During 
pregnancy there is an increased iodine 
excretion in the urine as a result of increased 
glomerular filtration and decreased renal 
tubular absorption. In addition, maternal iodine 
is actively transported to the feto-placental 
unit, which contributes to a state of relative 
iodine deficiency (8, 9). 
The other factor is the impact of HCG 
secreted by the placenta of humans. Thyroid 
stimulation in response to the thyrotropic 
activity of HCG overrides the normal action of 
the hypothalamic pituitary thyroid feedback 
system. TSH that can bind and transduce 
signaling from the TSH receptor on thyroid 
epithelial cells. Closure to the end of the first 
trimester of pregnancy in humans, when HCG 
levels reaches at peak, a substantial fraction 
of the thyroid-stimulating activity is from HCG. 
During this time, blood levels of TSH become 
suppressed. The thyroid-stimulating activity of 
HCG actually causes some women to cause 
transient hyperthyroidism (8, 9). 
The potential source of TH for the fetus is 
its own thyroid and the thyroid of the mother. 
Human fetuses acquire the ability to 
synthesize TH at approximately the first 
trimester of gestation. Current evidence from 
several species indicates that there is 
significant transfer of maternal THs across the 
placenta and also the placenta contains 
deiodinases that can convert T4 to T3 (10). 
Pregnant mother and infant protection is a 
priority in the health because these population 
groups are mostly exposed to the diseases 
and death. Thyroid dysfunction is one of the 
common complications of pregnancy and it 
contributes significantly to the maternal and 
fetus morbidity and mortality. There is limited 
attention and information related to thyroid 
dysfunction and its complication during 
pregnancy. Therefore, the aim of this review 
was to assess the magnitude of maternal and 
fetal thyroid dysfunction and its complication 
in pregnancy secondary to thyroid 
dysfunction. 
 
Thyroid hormone abnormalities during 
pregnancy 
 
Hyperthyroidism 
Hyperthyroidism typically is the disease 
process in which excessive TH is synthesized 
and excreted, whereas the term thyrotoxicosis 
refers to increased amounts of TH in the 
circulation (11). It can occur in approximately 
1% of the population and up to 0.4% of the 
pregnancies (12). Previous study by Wang et 
al found that the prevalence of thyroid 
dysfunction was 10.2%, hyperthyroidism, 
hypothyroidism and hypothyroxinemia were 
1.8, 7.5 and 0.9% respectively (13). 
There are 2 causes of hyperthyroidism, like 
classic causes which is found in the general 
population, and the other causes are specific 
during pregnancy. True hyperthyroidism is 
differentiated from other forms by elevated 
radioactive iodine uptake (RAIU). The other 
forms are differentiated from true 
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hyperthyroidism by decreased RAIU like 
hyperthyroidism caused by factors other than 
thyroid gland over-activity may result from 
inflammatory thyroid disease, pregnancy-
specific associations (like hyperemesis 
gravidarum and hydatid form mole) and the 
presence of ectopic thyroid tissue or by 
exogenous sources of TH (14-17).  
Tissue effects of hyperthyroidism include 
accelerated metabolism, suppressed serum 
TSH, low serum cholesterol, increased bone 
turnover and reduced bone density with an 
increased risk of osteoporosis and fracture 
(18). A study by Marvisi et al found that 
hyperthyroidism strongly is associated with 
lower TSH values and increased pulmonary 
arterial pressure which leads to severe 
pulmonary hypertension (19). In the first 
trimester of gestation, the normal elevation in 
total T4 and total T3, due to estrogen-induced 
increase in TBG concentration and HCG 
thyroid stimulation with suppression of serum 
TSH, may pause difficulties in the diagnosis of 
maternal hyperthyroidism (20). 
 
Characteristics of various types of 
hyperthyroidism 
TSH-induced hyperthyroidism: This type 
of hyperthyroidism is due to dysfunction in 
TSH that regulates T3 and T4 production. 
Increased stimulation by inappropriate TSH 
secretion may be caused by TSH-secreting 
pituitary adenomas that influences elevated 
TH synthesis and release, and not responsive 
to normal hormonal feedback control. 
Diagnosis is confirmed by demonstrating a 
lack of TSH response to thyrotropin releasing 
hormone (TRH) stimulation and radiologic 
imaging of the pituitary (21).  
Pituitary resistance to thyroid hormone: 
It refers to resistance of the pituitary to TH 
feedback control, possibly resulting from 
receptor modification. Diagnostically these 
patients display an appropriate increase in 
TSH in response to TRH and suppressed TSH 
in response to T3 (14).  
Hyperthyroidism from thyroid 
stimulators other than TSH: Graves’ disease 
(GD) is the most common cause of 
hyperthyroidism which is an autoimmune 
syndrome resulting from the production of 
thyroid stimulating antibodies (TSAbs), 
sometimes called TSHR Ab capable of 
stimulating thyroidal TSHRs, resulting in 
excessive TH production and release, and 
overstimulation of gland growth. 
Autoantibodies that react with the orbital 
muscle of the eye and fibroblasts of skin are 
also produced and initiate the extra thyroidal 
manifestations of GD (22, 23).  
Like other autoimmune diseases, the 
activity of GD is aggravated during the first 
trimester of gestation and decreased during 
the latter half of pregnancy, to be aggravated 
again in the first few months after delivery or 
late in the postpartum period (24, 25). Fetal 
effects of Graves hyperthyroidism are 
hyperthyroidism, intrauterine growth, 
retardation, short gestational age, still birth, 
craniosynostosis and also maternal effects are 
hypertension, preeclampsia, preterm delivery, 
heart failure, thyroid crisis and placental 
abruption (26).  
Trophoblastic disease: It is resulted from 
the production of thyroid stimulators other 
than TSH. It is a general term that includes 
benign and malignant conditions of 
hydatidiform mole with frequency of 
approximately 1 in 1500-2000 pregnancies 
and choriocarcinomas with frequency of 1 in 
40-60000 pregnancies (27, 28). The etiology 
of the hyperthyroidism is thought to be related 
to the increased levels of serum HCG in these 
patients (15). HCG is secreted by placenta 
from early pregnancy that shares a common 
alpha subunit with TSH. HCG stimulates the 
normal maternal thyroid via TSH receptor to 
synthesize and secrete TH (29).  
Hyperthyroidism attributable to 
trophoblastic disease should be suspected in 
patients who demonstrate increased free 
thyroxine (FT4) and free triiodothyronine (FT3) 
levels, decreased TSH, and significantly 
increased HCG (30). Although FT4 and FT3 
levels can be increased with HCG levels 
>50,000 IU/L in patients with trophoblastic 
tumors, serum HCG may reach >300,000 IU/L 
compared to the >50,000 IU/L seen in normal 
pregnancy (30). Thyrotoxic patients also have 
a higher serum T4 to T3 ratio than Graves’s 
patients (28).  
Gestational thyrotoxicosis: Gestational 
thyrotoxicosis is a transient increase in thyroid 
secretion leading to thyrotoxicosis of varying 
degrees of severity that can occur when HCG 
levels are very high and considered as a fairly 
normal phenomena. As HCG is a thyroid 
stimulator, a state of hyper stimulation of the 
thyroid gland is common in early pregnancy. 
This form of hyperthyroidism differs from GD 
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in that occurs in women without a past history 
of GD and in the absence of detectable 
TSHR-Ab (29, 31). This disorder occurs in 
0.2% of pregnancies. Mostly patients with 
hyperemesis gravidarum, as many as 60% 
exhibit hyperthyroidism (32, 33). Interestingly, 
more severe vomiting is associated with a 
greater degree of thyroid stimulation and 
higher level of HCG. On laboratory 
examination, the serum FT4 is more 
frequently increased compared with the serum 
FT3 level (34).  
The clinical importance of gestational 
transient thyrotoxicosis (GTT) has probably 
been overlooked. From recent studies, it is 
now thought that the prevalence of GTT may 
be as high as 2-3% of all pregnancies that is 
10-fold more frequent than hyperthyroidism 
due to GD (35). The syndrome GTT is 
important to differentiate from GD because the 
course of both conditions, the associated fetal 
risks, and the management and follow-up are 
entirely different (36, 37).  
Hyperthyroidism from thyroid gland 
autonomy: Toxic adenoma, as an 
autonomous thyroid nodule, is a discrete 
thyroid mass whose function is independent or 
normal pituitary control. These nodules may 
be toxic adenomas or hot nodules based on 
their uptake on radioiodine and appearance 
on a radioiodine thyroid scan. Toxic or hot 
nodules secrete THs independent of the 
pituitary because this tissue contains mutated 
TSHRs. Thyroxine levels typically are 
elevated in these patients sometimes only T3 
levels are increased (38). Consequently if T4 
concentrations are normal in such patients T3 
levels should be determined to rule out T3 
toxicosis.  
In toxic multinodular goiter, the thyroid 
gland normally enlarges in reaction to an 
increased demand for THs that occurs in 
pregnancy, iodine deficiency and 
immunologic, genetic disorders. During these 
phenomenon, there is increased TSH 
secretion and a compensatory increase in 
thyroid follicles and TH synthesis. When the 
situation for excessive production of TH 
subsides, TSH secretion decreases and the 
thyroid gland returns to normal size. However, 
permanent changes may have arisen in some 
follicle cells that can function autonomously 
relative to TSH. These autonomous follicles 
may produce excessive TH unregulated by 
TSH, resulting in thyrotoxicosis symptoms 
similar to GD without infiltrative ocular 
manifestations or myxedema (14, 38).  
Thyrotoxicosis associated with 
inflammatory thyroid disease: Subacute 
thyroiditis also called de Quervain’s thyroiditis, 
is a painful condition of the thyroid gland that 
appears to be due to viral invasion of the 
thyroid parenchyma and begins much more 
suddenly than Hashimoto's thyroiditis. 
Postpartum thyroiditis may be subclinical or 
produce only fragile clinical manifestations. If 
it is still present, thyroid function testing will 
show elevated TH levels and a suppressed 
TSH level. After the thyrotoxicosis decreases, 
the patient will be euthyroid for a few weeks. 
Then, because the thyroid has tired its store of 
hormone, hypothyroidism will develop. In 
response, the TSH level begins to rise in 
about one month, normal thyroid function is 
usually restored, rarely, the hypothyroid phase 
may be prolonged by 3-5 months, but rarely it 
is permanent (39, 40).  
Thyrotoxicosis caused by postpartum 
thyroiditis may be clinically identical to GD, 
which subsides during pregnancy and 
worsens immediately afterwards. The 
distinguishing feature is that in patients with 
GD, the thyroid actively produces hormone 
and so takes up radioiodine at 3-5 times the 
normal rate. On the contrary, the thyroid gland 
releases hormone into the serum in patients 
with postpartum thyroiditis (40). 
 
Ectopic thyroid tissue 
Struma ovarii and follicle cancer: A 
teratoid tumor of the ovary that is capable of 
producing TH is strauma ovarii. This is an 
extremely rare form of thyrotoxicosis and is 
evident by hyperthyroidism without thyroid 
gland enlargement and suppressed RAIU. 
The disease can be detected by whole body 
scanning with RAI. Both surgery and 
radioiodine therapy is required since the 
tissue is potentially malignant. TH with 
sufficient preserved function can be secreted 
to cause thyrotoxicosis in case of metastatic 
follicular carcinoma. In most of these cases 
there was a previous diagnosis of thyroid 
malignancy (21). 
Risks of hyperthyroidism on fetal and 
maternal well-being: Elevated levels of TH 
complicating pregnancy is not common, but 
potentially severe condition occurs in about 2 
out of 1000 pregnancies (41). Uncontrolled 
hyperthyroidism during pregnancy can 
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promote to congestive heart failure, 
preeclampsia, rise in blood pressure in late 
pregnancy, thyroid storma, miscarriage, 
premature birth and low birth weight (42). 
Hyperthyroidism in a newborn can result in 
rapid heart rate, which may lead to heart fail-
ure; early closure of the soft spot in the skull; 
poor weight gain; irritability; and sometimes an 
enlarged thyroid that can press against the 
windpipe and interfere with breathing (29). 
Autonomous production of TH and 
inadequately treated maternal hyperthyroidism 
may result in fetal and neonatal 
hyperthyroidism due to the trans-placental 
transfer of stimulatory TSHRAb (43, 44). 
Clinical neonatal hyperthyroidism occurs in 
about 1% of infants born to mothers with GD. 
Not often neonatal hypothyroidism may also 
be observed in the infants of mothers with 
Graves’ disease, this may result from trans 
placental transfer of circulating maternal anti-
thyroid drugs, pituitary-thyroid axis 
suppression from transfer of maternal T4 (45). 
Thyroid storm the most severe manifestation 
of hyperthyroidism results from untreated 
hyperthyroidism and may be precipitated by 
infection trauma, a surgical procedure and 
diabetic ketoacidosis (42, 46). Thyrotoxic 
periodic paralysis is another uncommon 
problem of hyperthyroidism. It is a reversible 
disorder characterized by acute muscle 
weakness and hypokalemia. The attacks of 
periodic paralysis are precipitated by 
hypokalemia that is caused by a transcellular 
shift rather than total body depletion of 
potassium (46).  
Diagnosis of hyperthyroidism: 
Measurement of the TSH level is the only 
initial test necessary in a patient with a 
possible diagnosis of hyperthyroidism without 
evidence of pituitary disease. If the TSH level 
is low, then FT4 should be measured to 
evaluate for thyrotoxicosis. Measurement of 
FT3 is helpful in the clinical diagnosis of 
thyrotoxicosis when the FT4 values are 
unexpectedly normal (47). Thyroid-stimulating 
antibody levels can be used to monitor the 
effects of treatment with anti-thyroid drugs in 
patients with GD (48). High iodine uptake is 
seen in disease that cause increased T4 
synthesis, including GD, toxic multinodular 
goiter, toxic adenoma and molar pregnancy. 
Low iodine uptake is seen disease that 
causes inflammation and release of T4 
including subacute thyroiditis, thyrotoxicosis 
factitia, iodine ingestion and post-partum 
thyroiditis (21, 49). 
Treatment of hyperthyroidism during 
pregnancy: Maternal and fetal outcome is 
directly associated to control of 
hyperthyroidism. During pregnancy, mild 
hyperthyroidism, in which TSH is low but FT4 
is normal, does not need treatment. More 
severe elevated TH concentration is treated 
with anti-thyroid medications. The medications 
cross the placenta in small amounts and can 
decrease fetal TH production, so the lowest 
possible dose should be used to avoid 
hypothyroidism in the baby. The medications 
can cause adverse effects in some people, 
like allergic reactions, patients with 
leucopenia, which can lower a person’s 
resistance to infection, liver failure, in rare 
cases (50, 51). Molar disease should also be 
considered and can potentially lead to 
fulminant hyperthyroidism, particularly in 
women with a pre-existing autonomous 
nodular goiter. However, uncomplicated 
hydatidiform mole is now easily diagnosed in 
the early stages of gestation and therefore, 
will rarely lead to severe hyperthyroidism, 
because it lasts only for a few weeks or 
months and is rapidly cured by the removal of 
the pathological trophoblast (51). 
 
Hypothyroidism 
 
It is the most common pathological 
deficiency of TH that accounts approximately 
2% of women and 0.1-0.2% of men (52). It is 
common in pregnancy with a predictable 
prevalence of 2-3% and 0.3-0.5% for 
subclinical and overt hypothyroidism 
respectively (53). Endemic iodine (I-) 
deficiency accounts for most hypothyroidism 
in pregnant women worldwide while 
Hashimoto’s disease is the supreme cause of 
hypothyroidism in I- adequate parts of the 
world (54). 
Manifestations of hypothyroidism can range 
from asymptomatic subclinical detection to 
overt myxedema, which is rarely seen due to 
widespread screening for thyroid disease (55). 
A cross sectional study conducted by Alkafajei 
et al found that the prevalence of sub clinical 
hypothyroidism was 4.3% and 20.8% 
according to the general laboratory and 
internationally adopted criteria respectively 
(56). Effects of hypothyroidism on the fetus 
like impaired brain development, intrauterine 
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death, low birth weight, neonatal respiratory 
distress, increased fetal distress and preterm 
birth  are commonly observed (57, 58). A 
study also reported by Renée et al and Negro 
et al showed that infants born to thyroid 
peroxidase (TPO) antibody positive mother 
and euthyroid pregnant women had 
significantly smaller head circumference, 
reduced brain weight and lower brain-to- body 
ratio than those born to TPO antibody 
negative mothers which is associated with an 
increased risk of miscarriage and premature 
delivers (57, 59).  
 
Characteristics of various types of 
hypothyroidism 
Hashimoto’s disease (Chronic 
autoimmune thyroiditis): It is the most 
common type of thyroiditis and the most 
common cause of primary hypothyroidism. In 
which the immune system attacks the thyroid, 
causing inflammation and interfering with its 
capacity to produce THs (25). Hashimoto's 
thyroiditis patients may develop a goiter or 
have thyroid atrophy. Patients with goiter may 
have antibodies that stimulate thyroid growth, 
whereas patients with an atrophic thyroid have 
antibodies that inhibit the trophic effects of 
TSH on the gland. Early Hashimoto’s 
thyroiditis is associated with a firm goiter, but 
later in the disease process a shrunken 
fibrotic hypo functioning thyroid gland 
develops (60, 61). Chronic autoimmune 
thyroiditis is the most important cause of 
hypothyroidism in up to 90% of pregnant 
women with hypothyroidism during pregnancy 
test positive for thyroid antibodies (53).  
The disease is characterized by the 
presence of high affinity and concentrations of 
serum thyroid antibody. The most frequently 
detected antibodies are TPO antibody and 
thyroglobulin antibody (TGAb). In its initial 
phase, Hashimoto’s thyroiditis can cause 
hyperthyroidism that presents as a painless 
goiter caused by lymphocytic infiltration of the 
thyroid gland. Positive TPO antibody and/or 
TGAb test results are found in approximately 
5% of euthyroid pregnant women. However, a 
thyroid autoantibody prevalence of up to 15% 
has been found in pregnant women (62). 
Postpartum thyroiditis: It is an 
inflammation of the thyroid gland that affects 
about 5-18% of healthy pregnant women in 
different populations during the first year after 
delivery (63). The hypothyroidism of these 
disease states results from inflammation 
secondary to infiltration of the gland by 
lymphocyte and leucocytes. Women have 
transient hyperthyroidism or hypothyroidism 
occurring 3-6 months after delivery that is 
associated with the development of a small, 
painless goiter. More than 90% of patients 
with thyroiditis recover wholly but the condition 
may relapse during second pregnancy. It 
should be noted that patients with postpartum 
hypothyroidism may present with postpartum 
depression. As much as 30% of cases after 3 
years, and in 50% at 7-10 years develop 
permanent hypothyroidism. Nearly all the 
women with postpartum thyroiditis have TPO 
antibody. This marker can be a useful 
screening test in early pregnancy as 50% of 
women with antibodies will develop thyroid 
dysfunction postpartum (64).  
Iatrogenic hypothyroidism: Iatrogenic 
hypothyroidism is resulted from thyroid 
surgery, exposure of the thyroid to external 
radiation for neck carcinomas or from RAI to 
treat GD. Typically hypothyroidism occurs 
within 1 month following total thyroidectomy 
and within 1 year after RAI therapy for GD 
(14).  
Iodine deficiency, thyroid enzyme 
defects, thyroid hypoplasia and 
goitrogens: Iodine deficiency or excess, and 
the ingestion of goitrogens may cause 
hypothyroidism on rare occasions by 
decreasing TH synthesis or release. Iodine 
deficiency, thyroid enzyme defects, thyroid 
hypoplasia and goitrogens may cause TH 
deficiency in a developing fetus, resulting in 
cretinism (14, 65). A study by Mezosi et al 
reported that the mean thyroid volume of 
women with severe iodine deficiency was 
significantly larger than that in the group with 
adequate iodine intake and the frequency of 
goiter was increased in all groups with iodine 
deficiency (66). 
Congenital hypothyroidism (CH): 
Congenital hypothyroidism (cretinism) is a TH 
deficiency at birth that occurs in 1/3000 
newborns, as a result of the absence of 
thyroid tissue (thyroid dysgenesis) and 
hereditary defects in TH biosynthesis. Thyroid 
dysgenesis occurs more commonly in female 
infants and permanent abnormalities occur in 
1 of every 4000 infants. It is one of the most 
common preventable causes of mental 
retardation. Most infants with CH do not show 
an obvious clinical manifestation of 
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hypothyroidism at birth. This may result from 
remaining neonatal thyroid function, because 
of an over expression of deiodinases by 
compensatory mechanisms in target organs, 
or in the TH received from breast milk (67).  
Risk of hypothyroidism on fetal and 
maternal well-being: Some similar problems 
caused by hyperthyroidism can occur with 
hypothyroidism. Uncontrolled hypothyroidism 
during pregnancy can lead to preeclampsia, 
anemia, abruption, miscarriage, low birth 
weight, stillbirth and rarely congestive heart 
failure (58). A study by Casey et al found that 
the three-fold risk of placental abruption and a 
two-fold risk of preterm delivery were reported 
in mother with sub-clinical hypothyroidism 
(68). Because of THs are crucial to fetal brain 
and nervous system development, 
uncontrolled hypothyroidism especially during 
the first trimester can affect the baby’s growth 
and brain development (58, 68).  
Previous study conducted by Haddow et al 
reported that untreated hypothyroidism during 
pregnancy can cause a significant decreased 
in the intelligence quotient of children (69). 
Two prospective studies showed that 
persistent hypothyroxinemia at 12 wk of 
gestation was associated with an 8-10 point 
deficit in mental and motor function scores in 
infant offspring compared to children of 
mothers with normal thyroid function and the 
first trimester maternal FT4 was a significant 
predictor of orientation scores. But the 
developmental scores were not influenced by 
further declines in maternal FT4 at 24 and 32 
wk gestation (70, 71). 
Management of hypothyroidism in 
pregnancy: Hypothyroidism is treated with 
synthetic TH called thyroxine (LT4) which is 
identical to the natural T4. Pregnant women 
with pre-existing hypothyroidism will need to 
increase their pre-pregnancy dose of T4 to 
keep normal thyroid gland function. Thyroid 
gland function should be monitored every 6 to 
8 weeks during pregnancy. Synthetic T4 is 
safe and necessary for the well-being of the 
fetus if the mother has hypothyroidism (72). 
Asymptomatic pregnant women should be 
routinely screened for hypothyroidism and 
patients with subclinical hypothyroidism 
should be treated to ensure a healthy 
pregnancy (73). A prospective intervention 
trial study found that treatment of 
hypothyroidism by LT4 reduces the risk of 
adverse maternal and fetal outcomes (60). 
Dietary Supplements like iodine is an 
important mineral for a mother in pregnancy, 
because the thyroid uses iodine to make TH. 
During pregnancy, the baby gets iodine from 
the mother’s diet. A woman requires more 
iodine when they are pregnant (74). Choosing 
iodized salt supplemented with I P-P over plain 
salt and prenatal vitamins containing IP-P will 
ensure dietary supplement. A prospective 
study conducted by Murcia et al found that 
women took mean dose of 100-149 ug/day 
during pregnancy, and their children showed a 
two point decreased in PDI compared with the 
children of mother taking <100 ug/day. This 
difference was greater when mother took 
>150 ug/day with a decreased of 5.5 points 
(75). 
 
Conclusion 
 
Different studies have showed that thyroid 
dysfunction is common in pregnancy. The 
major causes for this dysfunction is hormonal 
and metabolic changes during pregnancy 
leading to profound alterations of the 
biochemical parameters of the thyroid 
function. Understanding the normal 
physiological adaptation of the pituitary-
thyroidal axis in pregnancy enables us to 
manage cases of thyroid dysfunction. 
Uncorrected thyroid function in pregnancy has 
adverse effects on 61Tfetal61T and maternal well-
being. Thyroid disease usually affects females 
of the reproductive age group and caring for 
these women during pregnancy requires 
careful monitoring of both the mother and the 
fetus. Appropriate diagnosis, care and 
management of thyroid dysfunction in the pre-
pregnancy, pregnancy and post-pregnancy 
periods are important to minimize the risk of 
complications, long-term effects of the mother 
and fetus. 
 
Recommendation 
Clinical evaluation of the patient’s 
symptoms as well as laboratory testing should 
be done carefully to assess thyroid function 
during pregnancy. It is recommended that all 
pregnant mothers should be given thyroid 
function test and those who have thyroid 
dysfunction should be provided appropriate 
treatment and follow up until there will have 
normal thyroid function. Developmental follow-
up of the babies of thyroid dysfunction 
mothers is also recommended in order to 
Alemu et al 
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identify cognitive and other deficiencies as 
early as possible and provide appropriate 
management.  
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